Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Equity Average (2016 - 2025)

Haemonetics has reported Equity Average over the past 16 years, most recently at $880.3 million for Q4 2025.

  • For Q4 2025, Equity Average fell 1.4% year-over-year to $880.3 million; the TTM value through Dec 2025 reached $880.3 million, down 1.4%, while the annual FY2025 figure was $890.4 million, 0.16% changed from the prior year.
  • Equity Average for Q4 2025 was $880.3 million at Haemonetics, up from $865.7 million in the prior quarter.
  • Over five years, Equity Average peaked at $951.6 million in Q1 2024 and troughed at $687.8 million in Q4 2021.
  • A 5-year average of $820.1 million and a median of $846.4 million in 2023 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: grew 24.89% in 2021 and later fell 9.23% in 2025.
  • Year by year, Equity Average stood at $687.8 million in 2021, then rose by 9.4% to $752.5 million in 2022, then increased by 22.06% to $918.5 million in 2023, then dropped by 2.79% to $892.9 million in 2024, then dropped by 1.4% to $880.3 million in 2025.
  • Business Quant data shows Equity Average for HAE at $880.3 million in Q4 2025, $865.7 million in Q3 2025, and $851.6 million in Q2 2025.